Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | YAP1 | P46937 | 3/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631348 | 0.85 | SRD5A2 (0.59) | SRD5A2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL12420783 | 0.84 | SRD5A2 (0.69) | SRD5A2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL9410566 | 0.83 | SRD5A2 (0.64) | SRD5A2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2194947 | 0.81 | MEN1 (0.47) | MEN1KMT2ADRD2DRD3 | |
| SCHEMBL16598938 | 0.81 | DRD2 (0.55) | MEN1KMT2ADRD2DRD3 | |
| SCHEMBL5507380 | 0.79 | SRD5A2 (0.78) | SRD5A2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2198391 | 0.79 | KDM4E (0.60) | SRD5A2MEN1KMT2ADRD2DRD3 | |
| SCHEMBL4470968 | 0.79 | SRD5A2 (1.00) | SRD5A2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL7163869 | 0.78 | YAP1 (0.50) | MEN1KMT2AYAP1PRMT5GPR119 | |
| SCHEMBL12509065 | 0.77 | SRD5A2 (0.56) | SRD5A2MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | SRD5A2 1546/4885MEN1 4707/4885KMT2A 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.